VIMGF

Healthcare Diagnostics & Research

Vimian Group AB (publ)

$2.77
+0.00 +0.00% today

Price History

Not enough data

Key Stats

Market Cap
1.46B
Avg Volume
0
P/E (TTM)
39.57
EPS
$0.07
52W High
$3.01
52W Low
$2.68
Div. Yield
0.0%

Valuation

P/B Ratio
1.78
P/S Ratio
3.24
EV/EBITDA
2.09
EV/Revenue
0.53

Margins

Gross Margin 68.8%
Operating Margin 18.4%
Net Margin 8.2%
EBITDA Margin 25.3%

Growth & Returns

Revenue Growth (YoY)
16.6%
Earnings Growth (YoY)
0.2%
Earnings Growth (QoQ)
1.2%
Return on Equity
5.3%
Return on Assets
4.4%

Liquidity & Leverage

Current Ratio
2.43
Quick Ratio
1.35
Debt / Equity
0.37
Total Cash
51.60M
Total Debt
278.80M

About

Vimian Group AB (publ) engages in the animal health business worldwide. It operates through four segments: Specialty Pharma, MedTech, Diagnostics, and Veterinary Services. The company offers proprietary diagnostics, prescription, and non-prescription treatments for preventive care and treatment of chronic conditions for companion animals under the Nextmune brand name; and molecular and immunodiagnostic solutions that are used by laboratories for veterinary specific applications with a focus on livestock and companion animal health markets under the Indical Bioscience brand name. It also provides procurement and tech-driven operations, such as online marketing, education, and HR, as well as a community for veterinary clinics through a membership-based platform under the VetFamily brand name; and surgical and dental products to veterinary clinics and universities, including dentistry and companion animal orthopedics under the Movora brand name. Vimian Group AB (publ) was incorporated in 2020 and is headquartered in Stockholm, Sweden.

vimian.com